Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked
News
Aptevo Therapeutics has ended its partnership with MorphoSys AG for the development and commercialization of APVO414 as a treatment for metastatic castration resistant prostate cancer, or mCRPC. The termination means the company has ... Read more